A blood biomarker test for brain amyloid impacts the clinical evaluation of cognitive impairment

202333 citationsJournal Articlegold Open Access

Authors

Mark Monane · C2N Diagnostics (United States)

Kim G. Johnson · Duke University

B. Joy Snider · Washington University in St. Louis

Raymond Scott Turner · Georgetown University

Jonathan Drake · Brown University

Demetrius M. Maraganore · Tulane University

James L. Bicksel ·

Abstract

These findings demonstrate the clinical utility of the PrecivityAD blood test in clinical care and may have added relevance as new AD therapies are introduced.

Topics & Keywords

Dementia and Cognitive Impairment Research Alzheimer's disease research and treatments Health Systems, Economic Evaluations, Quality of Life

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Annals of Clinical and Translational Neurology

Volume 10, Issue 10, pp. 1738-1748

DOI: 10.1002/acn3.51863

Field-Weighted Citation Impact: 7.44